Fulcrum Therapeutics Inc (FULC) Stock: A Year of Stock Market Ups and Downs

The 52-week high and low prices can offer valuable insights into a stock’s current standing and prospects for future performance. Fulcrum Therapeutics Inc’s current trading price is -69.00% away from its 52-week high, while its distance from the 52-week low is 106.67%. The stock’s price range for this period has been between $2.25 and $15.00 The company’s shares, which are part of the Healthcare sector, had a trading volume of approximately 0.94 million for the day, a number notably lower than the average daily volume of 1.99 million over the last three months.

The present stock price for Fulcrum Therapeutics Inc (FULC) is $4.65. In the last trading session, the stock made a considerable jump, reaching $4.69 after an opening price of $4.15. The stock briefly fell to $4.15 before ending the session at $4.15.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


The market performance of Fulcrum Therapeutics Inc’s stock has been turbulent in recent times. Over the last year, the company’s stock reached its highest point at $15.00 on 01/13/23, while the lowest value for the same duration was $2.25 on 04/12/23.

Exploring Financial Performance and Market Capitalization: A Comprehensive Analysis

Fulcrum Therapeutics Inc (FULC) has experienced a quarterly decline of -14.36% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 287.46M and boasts a workforce of 89 employees.

Fulcrum Therapeutics Inc: What Analysts Are Saying

As of right now, 5 analysts are rating Fulcrum Therapeutics Inc as a BUY, 0 of the polled analysts branded the stock as an OVERWEIGHT, 1 analyst is recommending to HOLD this stock, 1 of them gave the stock UNDERWEIGHT rating, and 0 analyst is rating the stock as SELL.

Analyzing Trading Volume and Moving Average Trends

Based on Barchart.com data, the company’s moving average over the 100-day period was 4.16, with a change in price of +1.45. Similarly, Fulcrum Therapeutics Inc recorded 1,498,246 in trading volume during the last 100 days, posting a change of +45.31%.

Understanding Ticker ‘s Debt-to-Equity Ratio: An Analysis

The debt-to-equity (D/E) ratio serves as an important indicator of a company’s financial stability and market position. By dividing a company’s total liabilities by its shareholders’ equity, the D/E ratio reveals the degree to which a company relies on debt to finance assets compared to its shareholders’ equity. At the time of writing, the total D/E ratio for FULC stands at 0.04. Similarly, the long-term debt-to-equity ratio is also 0.04.

FULC Stock Stochastic Average

As of today, Fulcrum Therapeutics Inc’s raw stochastic average for the last 50 days stands at 65.65%. This is a decline compared to the raw stochastic average of the previous 20 days, which was noted at 97.42%. Furthermore, the company’s Stochastic %K and %D values for the past 20 days were 73.17% and 66.03%, respectively.

FULC Stock Price Performance Analysis

The stock price performance this year has been a mixed bag, which means people have different opinions about whether it’s been good or bad. Some may see it as optimistic, while others may view it as pessimistic. The index has shown a price loss of -36.13% this year. Over the last six months, there has been a weaker performance of 51.47%. The price of FULC fallen by 27.75% during the last 30 days period. For the last 5-days stocks have improved 34.01%.

Leave a Reply

Your email address will not be published. Required fields are marked *

On Key

Related Posts